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ABSTRACT We present a hypothesis for the loss of acetylcholine in Alzheimer's disease that is based on two recent
experimental results: that f3-amyloid causes leakage of choline across cell membranes and that decreased production of
acetylcholine increases the production of f-amyloid. According to the hypothesis, an increase in 3-amyloid concentration
caused by proteolysis of the amyloid precursor protein results in an increase in the leakage of choline out of cells. This leads
to a reduction in intracellular choline concentration and hence a reduction in acetylcholine production. The reduction in
acetylcholine production, in turn, causes an increase in the concentration of 13-amyloid. The resultant positive feedback
between decreased acetylcholine and increased 3-amyloid accelerates the loss of acetylcholine. We compare the predictions
of the choline-leakage hypothesis with a number of experimental observations. We also approximate it with a pair of ordinary
differential equations. The solutions of these equations indicate that the loss of acetylcholine is very sensitive to the initial rate
of f-amyloid production.
INTRODUCTION
The brains of patients with Alzheimer's disease (AD) are
characterized by the presence of plaques and tangles, by a
loss of neurons, and by a deficit of certain neurotransmit-
ters. There is evidence linking each of these characteristics,
as well as other effects of AD, to possible disease mecha-
nisms. For example, it has been proposed that amyloid
plaques cause AD by increasing intraneuronal calcium con-
centrations (Hardy and Higgins, 1992); that tangles cause
AD by interfering with neuronal plasticity (Callahan and
Coleman, 1995); that channels formed from f-amyloid
cause AD by providing a leakage pathway for calcium to
enter neurons (Arispe et al., 1993); and that acetylcholine
(ACh) loss causes AD by leading to the loss of phosphati-
dylcholine, and thus of the integrity of plasma membranes
(Wurtman, 1992).
One of these effects (or several other effects that have
been proposed) could be the primary cause of AD. Alter-
natively, there may be multiple causes. In either event, it is
useful to understand the relevant mechanisms. In this paper
we propose a specific mechanism for the observed deficit in
the concentration of ACh.
In our model, 13-amyloid-dependent leakage of choline
and ACh-dependent production of ,B-amyloid are reciprocal
effects that result in positive feedback and a large decrease
in the concentration of ACh. Several qualitative predictions
of this model agree with experiment. To obtain more quan-
titative predictions, we approximate the model by a pair of
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differential equations, and solve these equations numeri-
cally. The solutions describe the time course of the decline
in ACh concentration and its dependence on the initial rate
of ,-amyloid production.
CHOLINE-LEAKAGE HYPOTHESIS
We propose that an increase in the concentration of f-amy-
loid in brain tissue causes an increased leakage of choline
out of cholinergic neurons, thus decreasing the intracellular
choline concentration. Because intracellular choline is rate-
limiting for the production of ACh (Tucek, 1985), the
leakage of choline would also lead to a decrease in the
concentration of ACh. The putative outward leakage of
choline corresponds to passive movement of choline down
its electrochemical gradient. The intracellular choline con-
centration of cholinergic neurons is normally orders of
magnitude higher than the extracellular choline concentra-
tion because of active transport generated by the high-
affinity choline uptake system (Koliatsos and Price, 1991).
Thus there is a larger contribution to the electrochemical
gradient by the chemical gradient tending to drive choline
outward than by the electrical gradient tending to drive
choline inward.
This proposal was stimulated by evidence that ,B-amyloid
can cause ionic leakage in PC12 cells (Galdzicki et al.,
1994) and by the observation that AD patients have reduced
concentrations of intracellular choline (Nitsch et al., 1992),
despite an increase in the rate at which choline is pumped
into their cholinergic cells (Slotkin et al., 1990, 1994).
A decrease in ACh concentration has been shown to have
two effects relevant to the concentration of ,B-amyloid. It
causes an increase in the synthesis of amyloid precursor
protein (APP) in cerebral cortex, as reflected by increased
levels of APP mRNA (Wallace et al., 1993), and it favors
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the processing of APP by means of the ,B-amyloid pathway
(Buxbaum et al., 1994; Hung et al., 1993). Both effects tend
to increase the concentration of /-amyloid in response to a
decrease in ACh. Thus the proposed decrease in ACh
caused by an increase in ,B-amyloid and the resultant choline
leakage would lead to a further increase in ,3-amyloid and
hence a further decrease in ACh, resulting in a positive
feedback loop. Because of this positive feedback, eventually
there would be a significant decrease in ACh.
Let a extracellular concentration of ACh
Let b extracellular concentration of ,3-amyloid
We assume that the intracellular concentrations of cho-
line and acetylcholine are proportional to each other (Tucek,
1985) and to the extracellular concentration of acetylcho-
line. We also assume that the membrane concentration of
,3-amyloid is proportional to the extracellular concentration
of /3-amyloid. Then
da/dt = -klab
COMPARISON WITH EXPERIMENTAL DATA
The large decrease in ACh predicted by the choline-leakage
hypothesis is consistent with the dramatic decrease in ACh
that has been observed in the cerebrospinal fluid (CSF) of
patients with AD relative to age-matched controls (Tohgi et
al., 1994). This fractional loss is significantly larger than the
fractional loss of choline acetyltransferase activity (Slotkin
et al., 1994), indicating that there is not only a loss of
cholinergic cells in AD, but also that each surviving cell
produces less ACh.
Another prediction of the choline-leakage hypothesis is
that the loss of ACh in the brains of AD patients would be
accompanied by leakage of choline across their cell mem-
branes. This prediction is consistent with the decreased
concentration of intracellular choline in AD patients, evi-
denced by the decrease in choline observed in the frontal
cortex (Nitsch et al., 1992), and the increased concentration
of extracellular choline in AD patients, evidenced by the
increase in choline observed in the CSF (Elble et al., 1989).
Increased choline leakage in the brain cells of AD patients
is also consistent with the increased choline leakage ob-
served in their red cells (Butterfield et al., 1985).
It is paradoxical that in AD brains, the intracellular cho-
line concentration is decreased (Nitsch et al., 1992), even
though the choline transport rate is increased (Slotkin et al.,
1990, 1994). What happens to the extra choline that is
pumped into the cholinergic neurons of AD patients? The
choline-leakage hypothesis suggests a simple resolution of
the paradox: choline leaks out into the extracellular space.
According to this view, the increased choline transport is the
homeostatic response of cholinergic neurons to a loss of
intracellular choline.
MATHEMATICAL APPROXIMATION
The positive feedback inherent in the choline-leakage hy-
pothesis implies that the rate of decrease in ACh is very
sensitive to the initial rate of production of /3-amyloid. To
estimate this sensitivity quantitatively, we attempted to de-
scribe the relevant processes mathematically. Although an
exact description of these processes is quite complex, if a
few simplifying assumptions are made, as described below,
the essential aspects can be described by two ordinary
differential equations with two variables:
(1)
db/dt = k2- k3a - k4b (2)
where kl, k2, k3, and k4 are constants.
Equation 1 describes the loss of intracellular choline.
Because of the simplifying assumptions, this rate is propor-
tional to the time derivative of a. We assume that this rate
is also proportional to the intracellular concentration of
choline and to the membrane concentration of 63-amyloid, as
has been shown for PC12 cells (Galdzicki et al., 1994).
Because of the simplifying assumptions, these concentra-
tions are proportional to a and to b, respectively. Equation
2 describes the increase in the extracellular concentration of
,3-amyloid resulting from its formation from APP (repre-
sented by the term k2), the effect of extracellular ACh on the
rate of formation (Buxbaum et al., 1994; Hung et al., 1993;
Wallace et al., 1993) (represented by the term -k3a), and
the decrease in the extracellular concentration of f3-amyloid
resulting from enzymatic breakdown and absorption into
neuronal membranes (represented by the term -k4b). The
simultaneous solution of these two equations provides a
description of the time course of the decline in ACh con-
centration and the increase in /3-amyloid concentration.
The simplified model described above considers the re-
duction in ACh concentration caused by choline leakage,
but does not consider any additional reduction that might be
caused by the subsequent death of cholinergic neurons
(Yankner et al., 1990).
We used the Mathematica program to obtain numerical
solutions for the variables a and b. The assumed initial value
for b is zero. The initial value of a and the values for kl, k3,
and k4 were chosen to give concentrations of /3-amyloid and
ages for loss of acetylcholine that are close to physiological
values; these are indicated in the legend of Fig. 1. A range
of values was chosen for k2, the rate of /3-amyloid produc-
tion that would occur if no ACh or ,3-amyloid were present,
because the numerical solutions were found to be very
sensitive to the value of k2.
Fig. 1 shows the time course of the decline in ACh
concentration according to the simplified model. It can be
seen that ACh declines relatively slowly at first, and more
rapidly at a later age. Measurement of the CSF ACh con-
centration in AD patients and in age-matched controls
shows that the decline in CSF ACh concentration approxi-
mately parallels the severity of dementia (Davis et al., 1982;
Tohgi et al., 1994) and that a reasonable estimate of the
ACh concentration at the onset of AD is 30% of normal
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FIGURE 1 Calculated time course
of the decrease in ACh concentration
for several values of k2, the rate of
,B-amyloid production. Each curve is
labeled with the value of k2 in units
of nM/yr. Initial value of a = 50 nM;
k, = 7.5 ,uM-' year-'; k3 = 0.0042
year-'; k4 = 0.01 year-'. The hori-
zontal line, which corresponds to
30% of the initial ACh concentration,
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(Tohgi et al., 1994). Accordingly, a horizontal line repre-
senting 30% of the initial ACh concentration is drawn in
Fig. 1. The intersections of this line with the curves in Fig.
1 provide rough estimates of the predicted ages at which the
ACh concentration decreases to the level characteristic of
the onset of AD, and thus of the predicted age of onset of
AD itself. This correspondence is based simply on the
correlation between the loss of ACh and the onset of AD.
For the uppermost curve in Fig. 1, where k2 = 0.22
nM/yr, the age of onset is - 114 years. Thus this curve
pertains to an individual who is very unlikely to develop
AD. At the other extreme in Fig. 1, where k2 = 0.33 nM/yr,
50% higher than the value for the uppermost curve, the age
of onset is -50 years. This might correspond to an individ-
ual with Down's syndrome, because the presence of an extra
21st chromosome would be expected to cause a 50% in-
crease in APP (Rumble et al., 1989), and hence a 50%
increase in k2. Indeed, it is well documented that individuals
with Down's syndrome develop AD in middle age (Lai and
Williams, 1989; Mann, 1988; Wisniewski et al., 1985).
The dependence of the age of onset ofAD on the value of
k2 for the simplified model is shown in Fig. 2, where it can
be seen that the age of onset declines rapidly for small
increases in the value of k2. For example, an increase in k2
of 10% lowers the age of onset from 114 to 82, and an
increase of 20% lowers it to 68.
FIGURE 2 Dependence of calcu-
lated age of onset on k2. Age of onset
is determined by the intersection of
each time course curve with the hor-
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SIGNIFICANCE OF THE PREDICTIONS OF THE
MATHEMATICAL MODEL
It is interesting that, on the basis of a relatively small
amount of biological variability, the simplified model pre-
dicts a large variability in the age at which a dramatic loss
of ACh occurs. The relation between this large variability
and the large variability in the age of onset of AD itself may
be fortuitous. For example, several parallel processes asso-
ciated with AD may each involve positive feedback, which
is key to the predictions shown in Fig. 1. This could also
account for the correlation between decline in CSF ACh
concentration and increasing severity of dementia (Davis et
al., 1982; Tohgi et al., 1994). Alternatively, the large vari-
ability in age of onset may apply to both the decline in ACh
concentration and the development of AD because of a
causal relationship. ACh loss could be either a direct cause
or an indirect cause of AD.
Although the hypothesis proposed in this paper does not
depend on whether the loss of ACh leads to other charac-
teristics of AD, it is interesting to consider how such a loss
could cause further damage. One possibility is that de-
creased ACh could cause a loss of phosphatidylcholine, and
that depletion of this phospholipid would compromise the
properties of plasma membranes of cholinergic neurons,
leading to neuronal death (Wurtman, 1992). Another possi-
bility is that ACh is a neuronal trophic factor, analogous to
the many other neurotransmitters that have been shown to
act as trophic factors (Schwartz, 1992). There is also the
possibility that the reduction in ACh concentration is indi-
rectly responsible for neuronal death. This could occur by
means of a reduction in NGF concentration, as suggested by
the observation that NGF mRNA and NGF protein are
up-regulated in the rat hippocampus by the activation of
muscarinic receptors (Knipper et al., 1994). Thus a reduc-
tion in ACh concentration might be expected to cause
down-regulation of NGF. Another possibility is that a re-
duction in ACh concentration could increase the concentra-
tion of 13-amyloid by means of the positive feedback loop
described above, but a ,B-amyloid-dependent process, such
as calcium leakage (Arispe et al., 1993; Fukuyama et al.,
1994), could be the proximate cause of neuronal death. A
causal relation between loss of ACh and development of
AD could also provide a rationale for the earlier onset of
AD that has been found for individuals with apoE4, com-
pared to individuals with other alleles of APOE (Strittmatter
et al., 1993), because apoE4 is more effective in promoting
,B-pleated-sheet assembly (Castano et al., 1995). Such a
conformational change would increase the membrane par-
tition coefficient of /3-amyloid and hence would increase the
leakage of both choline and calcium.
The possibility that the loss of ACh is an important factor
in the overall development of AD (termed the "cholinergic
hypothesis" for AD) has been considered by many previous
authors (cf. reviews by Bartus et al., 1982, and Winblad et
al., 1993). One reason why interest in this hypothesis has
waned in recent years is the relatively minor improvement
obtained in clinical trials with either supplementary dietary
choline or with acetylcholinesterase inhibitors such as ta-
crine or donepezil hydrochloride (Wurtman, 1994). Accord-
ing to the choline-leakage hypothesis, even if the loss of
ACh were a basic cause of AD, it is unlikely that these
agents would be very effective, because by the time symp-
toms appear, there is already a significant loss of ACh and
a significant increase in membrane 3-amyloid. Thus even if
the treatments tended to increase the concentration of ACh,
choline leakage would continue because of the relatively
high concentration of ,B-amyloid already in the membranes.
In this regard, the difficulty associated with administration
of choline or acetylcholinesterase inhibitors after AD symp-
toms appear is somewhat analogous to the difficulty in
baling out a leaky boat without repairing the leak. Whether
choline or acetylcholinesterase inhibitors were administered
simply to counteract the loss of ACh in AD or to counteract
AD, itself, a more effective strategy would be to provide
these agents before the leak is serious, i.e., before AD
symptoms appear. Thus it might be reasonable to provide
acetylcholinesterase inhibitors (or any other pharmacologi-
cal agent believed to be efficacious in combating AD) to
asymptomatic individuals who have a very high probability
of developing AD, such as individuals with mutations
known to cause AD or individuals with Down's syndrome.
CONCLUSION
The choline-leakage hypothesis described in this paper is
consistent with a number of experimental observations,
some of which are difficult to explain by other models. One
goal of this presentation is to stimulate testing of the hy-
pothesis. There are also several implications regarding ther-
apeutic strategies that are inherent in the hypothesis. One
implication is that it is crucial to start therapy at an early
stage. Another is that it may be useful to seek agents that
can compete with or interfere with the putative f3-amyloid-
induced leakage.
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